- First drug target, the APP gene, identified by Dr. William Mobley and researchers at Stanford University, linking cognitive impairment in DS to the cognitive decline experienced in Alzheimer’s disease
- DSRTF awards grant to Dr. William Mobley (at the time with Stanford University, but currently at the University of California San Diego)
- New mouse model for Down syndrome research developed by researchers in London
- Decoding of human genome announced making cognitive research for Down syndrome more productive
As recently as 2004 there were no defined biological mechanisms known to have a direct correlation with cognitive impairment in Down syndrome, and as a result, no drug targets suitable for drug discovery and development. Since our founding in 2004 and over $7 million in research funding generated by DSRTF supporters, dramatic progress has been made. There are now five independent studies showing the promise for improving cognitive function for individuals with Down syndrome. Click here to learn more about our results.
DSRTF has become the leading non-governmental source of funding in the U.S. for research to improve cognition in individuals with Down syndrome. Since its founding in 2004, DSRTF has generated more than $9 million to fund and support major new results-driven cognition research.
For a copy of DSRTF's IRS 990 form for FY 2012, please e-mail us or visit guidestar.org.
Stanford University School of Medicine
More than $4.4 million total funding since 2004
Johns Hopkins University School of Medicine
More than $1.35 million total funding since 2007
University of Arizona
More than $440,000 total funding since 2008
University of California San Diego School of Medicine
More than $700,000 total funding since 2009
University of Texas, Austin
VA Palo Alto Health Care System